BriaCell Therapeutics Corp. (BCT.TO)
- Previous Close
4.4000 - Open
4.3400 - Bid 4.3300 x --
- Ask 4.6200 x --
- Day's Range
4.3400 - 4.5900 - 52 Week Range
4.3300 - 45.9000 - Volume
8,050 - Avg. Volume
16,846 - Market Cap (intraday)
29.408M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-6.5700 - Earnings Date Jun 12, 2025 - Jun 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
briacell.comRecent News: BCT.TO
View MorePerformance Overview: BCT.TO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCT.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCT.TO
View MoreValuation Measures
Market Cap
29.41M
Enterprise Value
22.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-158.14%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.59M
Diluted EPS (ttm)
-6.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.01M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.42M